Gallium Oxodotreotide

CHEMBL262135 Phase 4 Onaylandı Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A radioactive imaging agent used in PET scans to detect neuroendocrine tumors throughout the body. It attaches to specific receptors found on the surface of these tumors.

Terapötik Alanlar

Thyroid Cancer Breast Cancer Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A radioactive imaging agent used in PET scans to detect neuroendocrine tumors throughout the body. It attaches to specific receptors found on the surface of these tumors.

Yes, Gallium Oxodotreotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL262135. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Gallium Oxodotreotide PillFYI'da

Hızlı Veriler

Dış Bağlantılar

ChEMBL CHEMBL262135

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.